SCHEMBL1832401

SCHEMBL1832401

C=CC[C@]1(OC(=O)c2ccccc2)[C@@H](OC(=O)c2ccccc2)O[C@H](COC(=O)c2ccccc2)[C@H]1OC(=O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPT P10636 1/20 0.38
▸ POLB P06746 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ TDP1 Q9NUW8 2/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ SLC6A3 Q01959 1/20 0.35
▸ CHRNB2 P17787 1/20 0.34
▸ CHRNA5 P30532 1/20 0.34
▸ CHRNA7 P36544 1/20 0.34
▸ CHRNA4 P43681 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ PPM1B O75688 1/20 0.33
▸ GAPDH P04406 1/20 0.33
▸ CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1832400 1.00 ALDH1A1 (0.40) ALDH1A1MAPTPOLBGAAMAPK1
SCHEMBL9909462 1.00 ALDH1A1 (0.40) ALDH1A1MAPTPOLBGAAMAPK1
SCHEMBL16095893 0.88 ALDH1A1 (0.40) ALDH1A1MAPTPOLBGAAMAPK1
SCHEMBL24538656 0.87 ALDH1A1 (0.46) ALDH1A1MAPTPOLBGAAMAPK1
SCHEMBL20633050 0.85 ALDH1A1 (0.42) ALDH1A1MAPTPOLBGAAMAPK1
SCHEMBL13454886 0.85 ALDH1A1 (0.42) ALDH1A1MAPTPOLBGAAMAPK1
SCHEMBL16214812 0.85 ALDH1A1 (0.42) ALDH1A1MAPTPOLBGAAMAPK1
SCHEMBL16644506 0.83 ALDH1A1 (0.42) ALDH1A1MAPTPOLBGAAMAPK1
SCHEMBL12525577 0.83 ALDH1A1 (0.42) ALDH1A1MAPTPOLBGAAMAPK1
SCHEMBL15075395 0.83 ALDH1A1 (0.42) ALDH1A1MAPTPOLBGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2319853-B1 Process for the production of 2'-branched nucleosides IDENIX PHARMACEUTICALS INC (US) 2014-03-12 — — EP disclosed
EP-2319853-A1 Process for the production of 2'-branched nucleosides Idenix (Cayman) Limited (KY) 2011-05-11 — — EP disclosed
US-7598373-B2 Process for the production of 2-C-methyl-D-ribonolactone IDENIX PHARMACEUTICALS, INC. (US) 2009-10-06 — — US disclosed
US-20050020825-A1 Process for the production of 2'-branched nucleosides IDENIX PHARMACEUTICALS LLC 2005-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020825-A1 Process for the production of 2'-branched nucleosides RNGTT, MTAP, NSUN2 ALDH1A1 2027/4885MAPT 3665/4885POLB 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback